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Pharmacokinetics and Safety of Elotuzumab
Combined With Lenalidomide and
Dexamethasone in Patients With Multiple
Myeloma and Various Levels of Renal
Impairment: Results of a Phase Ib Study
Jesus Berdeja,1 Sundar Jagannath,2 Jeffrey Zonder,3 Ashraf Badros,4
Jonathan L. Kaufman,5 Robert Manges,6 Manish Gupta,7 Amol Tendolkar,7
Mark Lynch,8 Eric Bleickardt,8 Prashni Paliwal,8 Ravi Vij9
Abstract
Renal impairment is associated with a poor prognosis in patients with multiple myeloma (MM), and more treatment
options are needed. The pharmacokinetics of elotuzumab, a humanized IgG1 monoclonal antibody, combined with
lenalidomide and dexamethasone, is not signiﬁcantly different between patients with MM with and without renal
impairment, suggesting that elotuzumab might be administered without dose adjustment for renal function.
Introduction: The present study evaluated the pharmacokinetics and safety of elotuzumab, a humanized IgG1 monoclonal
antibody against signaling lymphocyte activation molecule-F7, combined with lenalidomide and dexamethasone, in patients
with multiple myeloma (MM) and renal impairment. Patients and Methods: Patients with MM and normal renal function (NRF)
(creatinine clearance [CrCl]  90 mL/min), severe renal impairment (SRI) (CrCl < 30 mL/min, not requiring dialysis), or endstage renal disease (ESRD) (requiring dialysis) were enrolled in this open-label, phase Ib study. Elotuzumab (10 mg/kg),
lenalidomide (5-25 mg), and dexamethasone (40 mg) were administered in 28-day cycles until disease progression or unacceptable toxicity developed. The primary endpoint was single-dose elotuzumab pharmacokinetics. Results: A total of 26
patients (median age, 63 years) were treated (NRF, n ¼ 8; SRI, n ¼ 9; ESRD, n ¼ 9). The median baseline CrCl was 105 mL/min
(range, 84-146 mL/min) for those with NRF and 26 mL/min (range, 15-33 mL/min) for those with SRI. Twenty-three patients (89%)
had received previous therapy (median, 2 regimens; range, 1-7). Treatment was discontinued in 6 patients with NRF, 4 with SRI,
and 5 with ESRD, primarily because of disease progression. The mean elotuzumab serum concentrations were comparable
across groups (n ¼ 23). No statistically signiﬁcant differences were observed in the maximum observed serum concentration,
area under the concentrationetime curve from time 0 to the last quantiﬁable serum concentration, or area under the concentration
etime curve from time 0 to inﬁnity when the SRI and ESRD groups were compared with the NRF group (P > .05). All patients had 
1 adverse event (AE). Of the 8 patients with NRF, 9 with SRI, and 9 with ESRD, 7, 8, and 7 experienced grade 3 to 4 AEs. The overall
response rates were 75% in the NRF, 67% in the SRI, and 56% in the ESRD groups. Conclusion: The results of the present
study support the use of elotuzumab for the treatment of patients with MM and renal dysfunction without dose adjustment.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 16, No. 3, 129-38 ª 2016 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Elotuzumab in Renally Impaired MM Patients
Introduction
Renal impairment is a common comorbidity associated with
multiple myeloma (MM), with  50% of patients affected during
the course of their disease1 and 10% requiring dialysis.2 In most
patients with MM, renal impairment is due to the overproduction of monoclonal free light chains, which causes cast
nephropathy (also known as myeloma kidney).1,3 Renal impairment is associated with poor outcomes4 and is an important
prognostic factor in MM. The median survival of patients with
MM and renal failure has been reported to be 19.5 months
compared with 40.4 months for patients without renal failure.5
Furthermore, the reversal of renal impairment in patients with
MM has been associated with an improved prognosis and longer
overall survival (OS).2,6
Advances in therapy, including the use of immunomodulatory
drugs (IMiDs) (eg, lenalidomide, thalidomide, and pomalidomide),
proteasome inhibitors (eg, bortezomib), and autologous stem cell
transplantation, have greatly improved the life expectancy of patients with MM, including those with impaired renal function.7,8
Continuous lenalidomide and dexamethasone in newly diagnosed
patients has demonstrated a median progression-free survival (PFS)
of 25.5 months and an OS at 4 years of 59%.9 The 1- and 3-year
PFS have also been shown to be superior in patients newly treated
with lenalidomide and dexamethasone compared with patients
treated with placebo and dexamethasone (78% and 52% vs. 52%
and 32%, respectively).10 Furthermore, the overall response and
very good partial response (VGPR) rates were 78% and 63% with
lenalidomide and dexamethasone and 48% and 16% with placebo
and dexamethasone, respectively. An overall response rate (ORR) of
64% was reported for patients with MM and impaired renal
function treated with lenalidomide combined with high-dose
dexamethasone, with improvements in renal function reported in
72% of patients with MM and mild-to-moderate renal impairment.11 However, because lenalidomide is excreted primarily
through the kidney, the half-life of the drug increases and drug
clearance decreases linearly with the severity of kidney impairment.
Thus, dose adjustments are required according to the creatinine
clearance (CrCl).11,12 Dimopoulos et al11 reported that a dose
reduction of lenalidomide or interruption because of adverse events
(AEs) was necessary in 22% of patients with MM and mild or no
renal impairment, 40% of patients with MM and moderate renal
impairment, and 38% of patients with MM and severe renal
impairment (SRI). Furthermore, patients with SRI treated with
lenalidomide plus dexamethasone have been shown to have shorter
OS compared with patients with mild or no renal impairment.11
Also, the response rate has been shown to decline with severity of
renal impairment.13 To improve the outcome of patients with MM
and renal impairment, new alternative efﬁcacious and well-tolerated
treatment options are necessary.
Elotuzumab is a humanized IgG1 immunostimulatory monoclonal
antibody targeted against signaling lymphocyte activation moleculeF7 (SLAMF7; also referred to as CS1), a glycoprotein expressed on
myeloma and natural killer cells but not on normal tissues.14
Through both direct activation and engagement of natural killer
cells, elotuzumab selectively targets and kills SLAMF7-expressing
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myeloma cells with minimal effects on normal tissue.15 A phase I
study assessing the safety, tolerability, pharmacokinetics (PK), and
pharmacodynamics of elotuzumab (dose range, 0.5-20 mg/kg every 2
weeks) demonstrated that elotuzumab was generally well tolerated at
doses sufﬁcient to achieve consistent SLAMF7 saturation (10 or 20
mg/kg).16 No objective responses were seen in this single-agent phase
I trial. However, 27% of patients achieved disease stabilization. A
phase Ib-II study investigating the safety and efﬁcacy of elotuzumab
combined with lenalidomide and dexamethasone demonstrated an
ORR of 82% in phase Ib,17 which compared favorably with the
historical response rate of 60% with lenalidomide and dexamethasone
alone in patients with relapsed or refractory MM (RRMM).18,19
Moreover, in phase II of the study, an ORR of 84% and PFS of
29 months were observed, and treatment was generally well
tolerated, with no dose-limiting toxicities reported.20 In the randomized, open-label phase III ELOQUENT-2 study, patients
treated with elotuzumab plus lenalidomide and dexamethasone
demonstrated an ORR of 79% compared with an ORR of 66% for
patients treated with lenalidomide and dexamethasone. A median
PFS of 19.4 months versus 14.9 months was observed in the
elotuzumab arm and lenalidomide/dexamethasone arm, respectively.21 Bortezomib signiﬁcantly enhanced elotuzumab activity in
a preclinical model,22 and a phase II, randomized, proof-ofconcept study demonstrated a median PFS of 9.7 months for
patients receiving elotuzumab combined with bortezomib and
dexamethasone versus 6.9 months for patients receiving bortezomib and dexamethasone.23
To determine whether elotuzumab could be safely administered
with lenalidomide and dexamethasone in patients with renal
impairment, the present phase Ib study was conducted to evaluate
the PK and safety of elotuzumab combined with lenalidomide and
dexamethasone in patients with MM and various levels of renal
function (normal renal function [NRF], SRI, and end-stage renal
disease [ESRD]).

Patients and Methods
Study Design
The present study was a phase Ib, multicenter, open-label study
(ClinicalTrials.gov identiﬁer, NCT01393964) of elotuzumab
combined with lenalidomide and dexamethasone in patients with
MM and NRF (CrCl  90 mL/min), SRI (CrCl < 30 mL/min
and not requiring dialysis), and ESRD (requiring dialysis). The
present study was conducted in accordance with Good Clinical
Practice, as deﬁned by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, and the ethical principles of the European
Union Directive and the US Code of Federal Regulations. All
patients (or, where necessary, legal guardians) provided written,
informed consent before participation. The present study was
conducted at 8 sites across the United States, with patients enrolled
from January 2012 to October 2013. The cutoff for data analysis
was June 30, 2014.
Treatment was administered in 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. The overall
study design is shown in Figure 1. During each cycle, elotuzumab
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Figure 1 Study Design Showing the Number of Patients Planned for Enrollment. aPremedication With an H1 Blocker
(Diphenhydramine, 25-50 mg, or Equivalent), an H2 Blocker (Ranitidine, 50 mg, Adjusted for Renal Failure, or Equivalent),
and Acetaminophen (650-1000 mg) Was Required 30-90 Minutes Before Elotuzumab Administration. bIn All Patients,
Lenalidomide Was Given Daily for 21 Days of a 28-day Cycle: Normal Renal Function (NRF), 25 mg Orally (p.o.) Once Daily;
Severe Renal Impairment (SRI), 15 mg p.o. Every 48 Hours; End-Stage Renal Disease (ESRD), 5 mg p.o. Once Daily. cWeeks
Without Elotuzumab: 40 mg p.o.; Weeks With Elotuzumab 8 mg Intravenously (I.V.) Plus 28 mg p.o.
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NRF (n = 8)

SRI (n = 8)

CYCLE 1

CYCLES 2 and 3

CYCLES 4+

STUDY DRUG ADMINISTRATION
Elotuzumaba
10 mg/kg IV
Day 1 only

STUDY DRUG ADMINISTRATION
Elotuzumaba
10 mg/kg IV
Days 1, 8, 15, 22

STUDY DRUG ADMINISTRATION
Elotuzumaba
10 mg/kg IV
Days 1, 15

Lenalidomideb

Lenalidomideb

Lenalidomideb

Dexamethasonec

Dexamethasonec

Dexamethasonec

ESRD (n = 8)

Tumor assessments every 4 weeks until progression (IMWG criteria)
(even if patient discontinues 1 or more study drugs, tumor assessments were continued until progression)

Abbreviation: IMWG ¼ International Myeloma Working Group.

was administered intravenously (I.V.) at a dose of 10 mg/kg. Lenalidomide was administered according to renal function (NRF, 25 mg
orally [p.o.] once daily; SRI, 15 mg p.o. every 48 hours; ESRD, 5 mg
p.o. once daily). Dexamethasone was administered at a dose of 40
mg p.o. on the weeks without elotuzumab infusion and at 8 mg I.V.
plus 28 mg p.o. on the weeks with elotuzumab infusion. A premedication regimen was administered 30 to 90 minutes before
elotuzumab administration and consisted of an H1 blocker
(diphenhydramine; 25-50 mg, or equivalent), an H2 blocker
(ranitidine; 50 mg, adjusted for renal failure, or equivalent), and
acetaminophen (650-1000 mg). Patients were given daily aspirin,
low-molecular-weight heparin, or warfarin, as clinically indicted, for
thromboembolic prophylaxis. Tumor assessment was performed
every 4 weeks until progression, death, or discontinuation from the
study, in accordance with the International Myeloma Working
Group (IMWG) criteria.24

Inclusion and Exclusion Criteria
All patients met the following criteria: age  18 years; documented evidence of symptomatic newly diagnosed MM or RRMM;
NRF, SRI, or ESRD; Eastern Cooperative Oncology Group performance status of  2; evaluable or measurable disease as deﬁned
by the IMWG.24 Previous lenalidomide treatment was permitted if
patients had not discontinued lenalidomide because of grade  3
treatment-related AEs.
The key exclusion criteria included previous or concurrent malignancy, monoclonal gammopathy of unknown signiﬁcance,
Waldenström’s macroglobulinemia, or smoldering myeloma; active
plasma cell leukemia; acute renal failure owing to readily reversible
causes; signiﬁcant cardiac disease; and previous therapy with elotuzumab or any IMiD (including pomalidomide), except for previous thalidomide or lenalidomide (as deﬁned in the inclusion
criteria).

Study Population
The safety population included all patients who had
received  1 dose of the study treatment. The PK population
included all patients who had received  1 dose of elotuzumab
and had stable renal function, determined by 2 creatinine
measurements  24 hours apart and within a 14-day screening
period. To ensure stable renal function, patients with a signiﬁcant change in renal function during cycle 1 (ie, level of renal
impairment improved or worsened in relation to enrollment
category) were excluded.

Study Objectives
The primary objective was to assess the effect of SRI and
ESRD on the single-dose PK of elotuzumab. The secondary
objective was to assess the safety of elotuzumab combined with
lenalidomide and dexamethasone in patients with MM, with or
without SRI or ESRD. Other exploratory objectives included the
efﬁcacy of elotuzumab combined with lenalidomide and dexamethasone in patients with SRI or ESRD and assessment of the
degree and rapidity of renal function improvement in patients
with SRI.

Assessments
During cycle 1, blood samples were collected before and at 10
points after elotuzumab administration to evaluate elotuzumab
single-dose PK. The PK assessments included the maximum
observed serum concentration (Cmax), area under the concentrationetime curve from time 0 to the last quantiﬁable serum
concentration [AUC(0eT)], area under the concentrationetime
curve from time 0 to inﬁnity [AUC(INF)], and total body clearance
(CLT). Additional samples were collected from patients with ESRD
immediately before and after dialysis. Elotuzumab serum
concentrations were assessed using a validated enzyme-linked
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Figure 2 Patient Disposition Flow Diagram. Nine Patients Did Not Enter the Treatment Period After Enrollment for the Following
Reasons: Platelet Count Too Low, No Longer Met Criteria for Severe Renal Impairment (SRI), Ineligibility, Best Response
Achieved Was Not at Least a Partial Response, Progression With Previous Lenalidomide Therapy, Previous Lenalidomide
Exposure Was Discontinued Because of a Grade 3 Adverse Event (AE), Lenalidomide Was Discontinued Because of a Grade 3
AE, Creatinine Clearance of 52 mL/min, and at the Decision of the Investigator (n [ 1 for All)

Abbreviations: ESRD ¼ end-stage renal disease; NRF ¼ normal renal function.

immunosorbent assay. Throughout the study, blood samples were
collected before elotuzumab administration for the detection of
antidrug antibodies and assessed using a validated enzyme-linked
immunosorbent assay. The ﬁrst sample was collected on day 1 of
cycle 1 and on day 1 of all subsequent cycles.
AE data were gathered through spontaneous reporting or openended questioning, examination, or evaluation. All serious
adverse events (SAEs) that occurred within 60 days of discontinuation of dosing or within 30 days of the last visit were
reported.
For the efﬁcacy assessments, the ORR (deﬁned as a partial
response or better) was evaluated every 4 weeks from the date of
the ﬁrst dose of the study drug using the IMWG response
assessment criteria. The criteria proposed by Dimopoulos et al25
were used to deﬁne the degree of renal response in the SRI group.
A minor renal response was deﬁned as sustained improvement of
baseline CrCl of < 15 mL/min to 15 to 29 mL/min or
improvement of the baseline CrCl of 15 to 29 mL/min to 30 to
59 mL/min.25
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Statistical Analysis
PK parameters were determined using WinNonlin, version 5.2 or
higher (Pharsight Corporation, Mountain View, CA). Analysis of
variance was performed on log-transformed AUC(0eT), AUC(INF),
and Cmax, with the renal function group as a ﬁxed effect to assess the
effect of renal impairment on elotuzumab PK.

Results
A total of 35 patients were enrolled. Of the 35 patients, 26 (74%)
were treated with elotuzumab combined with lenalidomide and
dexamethasone. However, 9 (26%) did not receive treatment
because they no longer met the study criteria (n ¼ 8) or at the
decision of the investigator (n ¼ 1; Figure 2). At the data cutoff
point, 11 patients (42%) were still receiving treatment (2 with NRF
[25%], 5 with SRI [56%], and 4 with ESRD [44%]), and 15 (58%)
had discontinued the study. The most common reason for
discontinuation was disease progression (Figure 2). One patient in
the NRF group was withdrawn from the study because of study
drug toxicity (infusion-related reaction).

Jesus Berdeja et al
Table 1 Baseline Characteristics
Characteristic

NRF (n [ 8)

SRI (n [ 9) ESRD (n [ 9)

Age (years)
Median

59.5

75.0

56.0

Range

42-68

63-87

39-80

Female sex

3 (38)

3 (33)

4 (44)

Race
White

8 (100)

6 (67)

1 (11)

Black or African
American

0

2 (22)

8 (89)

Asian

0

1 (11)

0
NAa

Creatinine clearance
(mL/min)
Mean

105

26

Range

84-146

15-33

I

1 (13)

2 (22)

2 (22)

II

3 (38)

4 (44)

1 (11)

III

3 (38)

3 (33)

6 (67)

NR

1 (13)

0

0

Newly diagnosed

1 (13)

2 (22)

0

Refractory

3 (38)

2 (22)

5 (56)

Relapsed

3 (38)

4 (44)

4 (44)

Unknownb

1 (13)

1 (11)

0

Yes

1 (13)

2 (22)

1 (11)

No

7 (88)

7 (78)

8 (89)

Yes

1 (13)

1 (11)

0

No

5 (63)

8 (89)

8 (89)

NR

2 (25)

0

1 (11)

Yes

1 (13)

1 (11)

0

No

6 (75)

8 (89)

9 (100)

NR

1 (13)

0

0

7 (88)

7 (78)

9 (100)

Median

2

2

2

Range

1-3

1-6

1-7

Bortezomib

5 (63)

7 (78)

9 (100)

Thalidomide

3 (38)

3 (33)

5 (56)

Lenalidomide

5 (63)

2 (22)

2 (22)

ISS disease stage

Disease status

Cytogenetics
del(17p)

t(14;16)

t(4;14)

Patients with 1
previous line of
therapy
Previous regimensc

Patients with previous
therapies

Data presented as n (%), unless otherwise noted.
Abbreviations: ESRD ¼ end-stage renal disease; ISS ¼ International Staging System; NA ¼ not
available; NR ¼ not reported; NRF ¼ normal renal function; SRI ¼ severe renal impairment.
a
Creatinine clearance was not required for patients in the ESRD group.
b
Refractory status to most recent line of therapy unknown.
c
Number of previous regimens applicable only to patients with relapsed or refractory
disease.

The baseline demographics are listed in Table 1. The patients
in the SRI group were slightly older, and a greater proportion of
patients in the ESRD group were black or African American and
had stage III disease (according to the International Staging
System). A total of 23 patients (89%) had received previous
therapy for MM, which included bortezomib (81%), thalidomide
(42%), and lenalidomide (35%). Three patients (12%) had newly
diagnosed MM, and 21 (81%) had RRMM. A greater proportion
of patients in the ESRD group had disease refractory to their
most recent line of therapy (NRF, 38%; SRI, 22%; and ESRD,
56%).
The patients received a median of 6.5 (range, 2-23), 16.0 (range,
2-25), and 9.0 (range, 2-25) treatment cycles in the NRF, SRI, and
ESRD groups, respectively. The median duration of treatment for
the NRF, SRI, and ESRD groups was 5.4 months (range, 1.0-21.7
months), 15.5 months (range, 1.4-23.7 months), and 8.1 months
(range, 1.0-23.0 months) for elotuzumab; 5.7 months (range, 0.521.8 months), 7.2 months (range, 0.3-21.6 months), and 8.6
months (range, 0.7-22.8 months) for lenalidomide; and 5.6 months
(range, 1.0-21.7 months), 15.5 months (range, 1.4-23.8 months),
and 8.1 months (range, 1.0-23.1 months) for dexamethasone,
respectively. The median duration of treatment was lower for the
NRF group than for the SRI and ESRD groups because patients
discontinued treatment < 6 months from study initiation owing to
infusion reaction in 1, physician’s request for 2, and progressive
disease after an initial response of stable disease and a partial
response in 1 each.
With regard to the relative dose intensity, 5 patients (63%) in the
NRF group, 6 (67%) in the SRI group, and 5 (56%) in the ESRD
group received  90% of the planned elotuzumab dose. Two patients in each group (NRF, 25%; SRI, 22%; ESRD 22%) received
80% to < 90% of the planned elotuzumab doses. Two patients
(25%) in the NRF group, 4 (44%) in the SRI group, and 3 (33%)
in the ESRD group received  90% of the planned lenalidomide
dose. Two patients (25%) in the NRF group, 4 (44%) in the SRI
group, and 1 (11%) in the ESRD group received  90% of the
planned dexamethasone dose.

Elotuzumab PK
The mean elotuzumab serum concentration proﬁles were
comparable across all treatment groups after single-dose administration in cycle 1 (Figure 3A). No statistically signiﬁcant differences were observed in Cmax, AUC(0eT), or AUC(INF) between
the SRI and ESRD groups and the NRF group (Table 2;
Figure 3B and C).
Minor differences in AUC(INF) were observed among the groups.
A trend was seen toward a greater AUC(INF) in the SRI and ESRD
groups than in the NRF group, although these differences were not
statistically signiﬁcant. In an exploratory analysis, relatively smaller
differences in AUC(INF) were observed among the 3 groups after the
exclusion of 3 patients (2 in the NRF group and 1 in the ESRD
group) who had developed antidrug antibodies on day 1 of cycle 2.
The mean AUC(INF) after exclusion of these 3 patients was 53,062,
60,255, and 56,093 mg.h/mL for the NRF, SRI, and ESRD groups,
respectively. The mean elotuzumab CLT values were similar among
the 3 groups (Table 2).
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A

300

Mean (SD) serum elotuzumab
concentration (µg/mL)

Figure 3 Elotuzumab Pharmacokinetics (PK) Values Stratiﬁed by Renal Functiona: (A) Elotuzumab Serum Concentration Proﬁles Over
Time From Initial Elotuzumab Doseb; (B) Maximum Observed Serum Concentration (Cmax); (C) Area Under the ConcentrationeTime
Curve From Time 0 to Inﬁnity [AUC(INF)]. aThree Patients Were Excluded From the PK Summary Statistics Because of a Dosing
Error (End-Stage Renal Disease [ESRD] Group, n [ 1), Estimated Glomerular Filtration Rate (eGFR) Outside the Value Limit
Range (Severe Renal Impairment [SRI] Group, n [ 1), and Limited Samples or Biologically Implausible Time Corresponding
to Cmax (Tmax) at 672 Hours (SRI Group, n [ 1). bMean 48-hour Dialysis Values Were Excluded in 1 Patient

250

NRF (n = 8)
SRI (n = 7)
ESRD (n = 8)

275
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200
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125
100
75
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0
0
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Time (h)

B

400
350

Cmax (µg/mL)

300
250
200
150
100
50
0
NRF

SRI

ESRD

(n = 8)

(n = 7)

(n = 8)

Renal function group

C

100000

AUC(INF) (h•µg/mL)

80000

60000

40000

20000

0
NRF

SRI

ESRD

(n = 8)

(n = 7)

(n = 8)

Renal function group

Abbreviations: NRF ¼ normal renal function; SD ¼ standard deviation.
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Table 2 Elotuzumab PK Parameters

Renal Function
Groupa
NRF
SRI
ESRD
SRI vs. NRF (%)
ESRD vs. NRF (%)

Geometric Mean
(% CV)

Adjusted Geometric Mean (90% CI)
Cmax (mg/mL)
217
226
218
104
100

(192-245; n ¼ 8)
(198-257; n ¼ 7)
(193-246; n ¼ 8)
(87-125; P ¼ .704)
(85-119; P ¼ .965)

AUC(0eT) (mg.h/mL)
39,559
50,080
45,937
127
116

(32,635-47,953; n ¼ 8)
(40,769-61,518; n ¼ 7)
(37,896-55,684; n ¼ 8)
(96-168; P ¼ .164)
(89-152; P ¼ .355)

AUC(INF) (mg.h/mL)
46,401
60,225
51,227
130
110

(36,221-59,442; n ¼ 8)
(46,238-78,522; n ¼ 7)
(39,310-66,756; n ¼ 8)
(90-187; P ¼ .228)
(77-159; P ¼ .642)

CLT (mL/h/kg)
0.22 (46; n ¼ 8)
0.17 (28; n ¼ 7)
0.20 (54; n ¼ 8)
NA
NA

Abbreviations: AUC(0eT) ¼ area under the concentrationetime curve from time 0 to the last quantiﬁable serum concentration (calculated by log- and linear-trapezoidal summations); AUC(INF) ¼ area
under the concentrationetime curve from time 0 to inﬁnity; CI ¼ conﬁdence interval; CLT ¼ total body clearance; Cmax ¼ maximum observed serum concentration; CV ¼ coefﬁcient of variation;
eGFR ¼ estimated glomerular ﬁltration rate; ESRD ¼ end-stage renal disease; NRF ¼ normal renal function; PK ¼ pharmacokinetics; SRI ¼ severe renal impairment; Tmax ¼ time corresponding to
Cmax.
a
Three patients were excluded from the PK summary statistics because of a dosing error (ESRD group, n ¼ 1), being outside the range of eGFR value limits (SRI group, n ¼ 1), and having limited
samples/biologically implausible Tmax at 672 hours (SRI group, n ¼ 1).

Safety
All patients experienced  1 AE. A summary of AEs occurring
in  3 patients in any 1 study group is provided in Table 3. Fatigue,
diarrhea, back pain, constipation, and anemia were the most
frequently reported AEs (Table 3). Overall, 3 of 26 patients (12%)
experienced grade 2 infusion reactions (1 in the NRF group and 2
in the ESRD group).
AEs led to treatment discontinuation in 4 patients (1 in the NRF
group [13%] and 3 in the SRI group [33%]). In the NRF group,
discontinuation was because of an infusion-related reaction in 1
patient. In the SRI group, discontinuation was because of a soft
tissue infection, increased blood creatinine level and psychiatric
disorder (agitation), and a skin and subcutaneous tissue disorder
(drug eruption) in 1 patient each. The AEs leading to discontinuation were grade 2 and 3 in severity and were considered to be
related to study treatment, except for the elevation in the blood
creatinine level.
SAEs were reported in 3 patients (38%) in the NRF group (all
grade 3 or 4), 5 (56%) in the SRI group (grade 3 or 4 in 3 [33%]),
and 7 (78%) in the ESRD group (grade 3 or 4 in 6 [67%]).
Pneumonia (NRF group, n ¼ 1; ESRD group, n ¼ 1) and upper
respiratory tract infection (SRI group, n ¼ 1; ESRD group, n ¼ 1)
were the most common grade 3 and 4 SAEs. No deaths occurred.

Efﬁcacy
Elotuzumab combined with lenalidomide and dexamethasone
resulted in overall responses in 6 (75%), 6 (67%), and 5 (56%)
patients in the NRF, SRI, and ESRD groups, respectively (Table 4).
A VGPR or better was observed in 3 (38%), 5 (56%), and 1 (11%)
patients in the NRF, SRI, and ESRD groups, respectively.
A minor renal response, based on the estimated CrCl values, was
observed in 2 patients (22%) in the SRI group (Table 4). These
occurred in 1 patient with newly diagnosed MM and 1 patient with
relapsed MM. No patient achieved a complete or partial renal
response across all groups.

Discussion
The ﬁndings from the present phase Ib study indicate that renal
dysfunction (SRI or ESRD) does not signiﬁcantly affect elotuzumab
PK when administered in combination with lenalidomide and
dexamethasone. These data suggest that elotuzumab 10 mg/kg,

combined with lenalidomide and dexamethasone, can be administered safely to patients with MM and SRI or ESRD without the
need to adjust the dose of elotuzumab according to renal function.
A trend toward a greater AUC(INF) was observed in patients with
renal dysfunction compared with patients with NRF. However,
slight differences in elotuzumab PK exposure seem unlikely to affect
clinical efﬁcacy. The presence of antidrug antibodies can affect the
PK of biologic compounds.26 The exclusion of 3 patients positive
for antidrug antibodies resulted in a smaller difference in the
AUC(INF) among the 3 patient cohorts; however, additional investigation would be required to conﬁrm the effect of antidrug antibodies on the systemic clearance of elotuzumab. Furthermore, based
on PK analyses performed in 375 patients across elotuzumab trials,
no effect on the glomerular ﬁltration rate (range, 4.58-124 mL/min/
1.73 m2) has been observed after elotuzumab administration
(Bristol-Myers Squibb; data on ﬁle). The absence of a relationship
between renal function and elotuzumab PK is consistent with renal
physiology, because the large size of elotuzumab (approximately 144
kDa) is expected to prevent it from being ﬁltered through the
glomerulus and eliminated by the kidney.27 The mean serum elotuzumab concentrations in the pre- and postdialysis blood samples
were comparable, demonstrating that elotuzumab is not likely to be
extracted to a signiﬁcant extent in the dialysate.
The tolerability of elotuzumab combined with lenalidomide and
dexamethasone across all classes of renal function is consistent with
what has been previously described for lenalidomide plus dexamethasone alone. Treatment discontinuation in the present study
most commonly resulted from disease progression, with AEs leading
to treatment discontinuation in 1 patient with NRF and 3 patients
with SRI. Moreover, grade 2 infusion reactions were only experienced by 3 patients: 1 in the NRF group and 2 in the ESRD group,
suggesting that the rate of infusion-related reactions did not appear
increased in patients with compromised renal function.
Efﬁcacy was evaluated in an exploratory manner owing to the
small sample size in the present study. However, the ORR in the
NRF group was consistent with that previously reported for elotuzumab combined with lenalidomide and dexamethasone.17 As
reported in other studies of patients with renal impairment, ORR
was progressively lower for patients with SRI and ESRD.11,13
However, a VGPR or better was observed in  1 patient across
all groups. Furthermore, a minor improvement in renal function
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Table 3 Adverse Events in ‡ 3 More Patients in Any Study Groupa
NRF (n [ 8)
Preferred Term

SRI (n [ 9)

ESRD (n [ 9)

Any Grade

Grade 3-4

Any Grade

Grade 3-4

Any Grade

Grade 3-4

Total patients with AE

8 (100)

7 (88)

9 (100)

8 (89)

9 (100)

7 (78)

Musculoskeletal and connective
tissue disorders

8 (100)

1 (13)

7 (78)

1 (11)

5 (56)

1 (11)

Back pain

3 (38)

0

3 (33)

1 (11)

4 (44)

0

Muscle spasms

3 (38)

0

1 (11)

0

1 (11)

0

7 (88)

0

7 (78)

1 (11)

7 (78)

1 (11)

Constipation

6 (75)

0

3 (33)

0

1 (11)

0

Diarrhea

2 (25)

0

5 (56)

1 (11)

4 (44)

1 (11)

Nausea

2 (25)

0

1 (11)

0

3 (33)

0

Stomatitis

1 (13)

0

4 (44)

0

1 (11)

0

7 (88)

2 (25)

7 (78)

0

9 (100)

1 (11)

Fatigue

6 (75)

2 (25)

4 (44)

0

6 (67)

0

Pyrexia

4 (50)

0

1 (11)

0

4 (44)

0

Malaise

3 (38)

0

1 (11)

0

0

0

Peripheral edema

1 (13)

0

4 (44)

0

4 (44)

0

6 (75)

4 (50)

6 (67)

4 (44)

6 (67)

4 (44)

Neutropenia

3 (38)

2 (25)

1 (11)

1 (11)

1 (11)

1 (11)

Anemia

2 (25)

0

5 (56)

2 (22)

3 (33)

0

Gastrointestinal disorders

General disorders and
administration-site conditions

Blood and lymphatic system
disorders

1 (13)

0

4 (44)

1 (11)

3 (33)

1 (11)

Infections and infestations

Thrombocytopenia

6 (75)

2 (25)

6 (67)

1 (11)

4 (44)

3 (33)

Skin and subcutaneous tissue
disorders

6 (75)

0

6 (67)

1 (11)

4 (44)

0

4 (50)

0

1 (11)

0

0

0

Hyperhidrosis
Rash

2 (25)

0

4 (44)

0

1 (11)

0

Pruritus

1 (13)

0

0

0

3 (33)

0

Metabolism and nutrition disorders

5 (63)

2 (25)

7 (78)

3 (33)

6 (67)

3 (33)

Hyperglycemia

3 (38)

1 (13)

3 (33)

2 (22)

2 (22)

1 (11)

Hypokalemia

1 (13)

0

3 (33)

1 (11)

3 (33)

0

Decreased appetite

0

0

2 (22)

0

3 (33)

0

Hypocalcemia

0

0

3 (33)

0

3 (33)

2 (22)

Nervous system disorders

5 (63)

0

7 (78)

4 (44)

4 (44)

0

Peripheral neuropathy

2 (25)

0

1 (11)

0

3 (33)

0

0

0

4 (44)

4 (44)

0

0

Syncope
Psychiatric disorders

5 (63)

0

2 (22)

0

3 (33)

0

Respiratory, thoracic, and
mediastinal disorders

5 (63)

2 (25)

5 (56)

0

3 (33)

1 (11)

4 (50)

0

2 (22)

0

1 (11)

0

3 (38)

1 (13)

2 (22)

0

2 (22)

1 (11)

4 (50)

0

0

0

2 (22)

1 (11)

Cough
Dyspnea
Cardiac disorders
Eye disorders

3 (38)

0

2 (22)

1 (11)

1 (11)

0

Investigations

2 (25)

0

7 (78)

2 (22)

3 (33)

2 (22)

Increased blood creatinine

0

0

5 (56)

1 (11)

1 (11)

1 (11)

Injury, poisoning, and procedural
complications

1 (13)

0

4 (44)

0

2 (22)

0

Renal and urinary disorders

1 (13)

0

3 (33)

1 (11)

0

0

Vascular disorders

1 (13)

0

4 (44)

3 (33)

2 (22)

1 (11)

Data presented as n (%).
Abbreviations: AE ¼ adverse event; ESRD ¼ end-stage renal disease; NRF ¼ normal renal function; SRI ¼ severe renal impairment.
a
No grade 5 events occurred.
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Table 4 Efﬁcacy Stratiﬁed by Renal Function
Treatment
Response

NRF (n [ 8)

with MM and renal impairment.

SRI (n [ 9) ESRD (n [ 9)

Best overall response
Stringent complete
response

0

Complete response

2 (25)

0

0

Very good partial
response

1 (13)

4 (44)

1 (11)

Partial response

3 (38)

1 (11)

4 (44)

Minor response

0

3 (33)

2 (22)

Stable disease

1 (13)

0

1 (11)

0

0

0

Not evaluable

1 (13)

0

1 (11)

ORR (%; 95% CI)

6 (75; 35-97)

6 (67; 30-93)

5 (56; 21-86)

Renal responsea

0

2 (22)

0

Progressive disease

1 (11)

0

Data presented as n (%), unless otherwise noted.
Abbreviations: CI ¼ conﬁdence interval; ESRD ¼ end-stage renal disease; NRF ¼ normal renal
function; ORR ¼ overall response rate; SRI ¼ severe renal impairment.
a
Minor renal response.

was observed in 2 patients with SRI, 1 of whom had relapsed disease. The ORRs in the present study compared favorably with
previously published rates for lenalidomide and dexamethasone
(present study, 75%, 67%, and 56% for NRF, SRI, and ESRD,
respectively, compared with 67%, 60%, and 49% for patients with
NRF, SRI, and moderate/severe renal function, respectively, for
lenalidomide and dexametheasone13). However, the small number
of patients in the present study precluded any deﬁnitive comparison. In a large randomized trial, the addition of elotuzumab to
lenalidomide and dexamethasone improved the overall response
rates by 13% compared with lenalidomide and dexamethasone
alone, an incremental beneﬁt similar to that seen in the present
study.21 Together, these ﬁndings support the feasibility of using
elotuzumab combined with lenalidomide and dexamethasone in
patients with MM and renal impairment and demonstrate that dose
adjustments for elotuzumab are not required in this patient
population.

Conclusion
The results of the present study support the use of elotuzumab
without dose adjustment for the treatment of patients with MM
and renal dysfunction. Elotuzumab combined with lenalidomide
and dexamethasone was tolerated and efﬁcacious for the treatment
of patients with MM and renal dysfunction, including ESRD,
and might be a new therapy option for this patient population.
Ongoing phase III studies are investigating the efﬁcacy of elotuzumab combined with lenalidomide and dexamethasone in patients with RRMM (ELOQUENT-2 study; ClinicalTrials.gov
identiﬁer, NCT01239797) or newly diagnosed or previously untreated MM (ELOQUENT-1 study; ClinicalTrials.gov identiﬁer,
NCT01335399).

Clinical Practice Points
 Renal impairment affects  50% of patients with MM during

the course of the disease and is associated with a poor prognosis.

 Elotuzumab, a humanized IgG1 monoclonal antibody targeted

against SLAMF7, in combination with lenalidomide and dexamethasone, may be used without elotuzumab dose adjustment
(but with a lenalidomide dose adjustment) for renal function in
patients with MM.
 Renal function does not signiﬁcantly affect the PK of elotuzumab when administered with lenalidomide and
dexamethasone.
 Elotuzumab, combined with lenalidomide and dexamethasone,
is well tolerated in patients with MM, regardless of their renal
function.
 Elotuzumab, combined with lenalidomide and dexamethasone,
can be a promising new therapy for the treatment of patients
with MM and renal dysfunction.
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